+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Radiation Dermatitis - Epidemiology Insight - 2030

  • ID: 5306991
  • Report
  • March 2021
  • Region: Global
  • 100 pages
  • DelveInsight
1 of 2
This ‘Radiation Dermatitis (RD) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of and historical and forecasted epidemiology of Radiation Dermatitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Radiation Dermatitis Disease Understanding

Radiation dermatitis (also called Radiodermatitis) is a condition caused by radiotherapy (X-Rays) delivered during cancer management. Pathophysiology of radiation dermatitis is a combination of radiation injury and the subsequent inflammatory response and can occur at both the irradiation entrance and exit site. Radiation dermatitis usually begins to occur within 1¬-4 weeks of treatment and persists for radiation therapy duration. It may require 2-4 weeks to heal after completion of treatment.

Radiation dermatitis (RD) affects nearly 95% of patients who receive radiation for cancer treatment, wherein ~70% of patients have moderate-to-severe skin reactions. Certain treating drugs (termed ‘‘radiosensitizers'') combined with radiation therapy can result in an increased incidence and severity of radiation-induced skin reactions by causing increased cellular damage and impaired cellular repair.

Radiation Dermatitis Epidemiology

The RD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The total incident cases of Radiation Dermatitis patients are increasing in the 7MM during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Radiation Dermatitis symptoms epidemiology segmented as the Radiotherapy Utilization, Incidence of Radiation Dermatitis, Grade-specific cases of Radiation Dermatitis, and Treated cases of Radiation Dermatitis. The report includes Radiation Dermatitis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Radiation Dermatitis Epidemiology

The epidemiology segment also provides the Radiation Dermatitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of incident cases of Radiation Dermatitis associated in 7MM countries was 3,012,048 in 2020.
  • As per the estimates, the United States has the largest incident population of Radiation Dermatitis.
  • Among the EU5 countries, Germany had the highest incident cases of Radiation Dermatitis, followed by France. On the other hand, Spain had the lowest incident cases, with 151,518 cases in 2020.
Scope of the Report
  • The Radiation Dermatitis report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The Radiation Dermatitis epidemiology report and model provide an overview of Radiation Dermatitis's risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into Radiation Dermatitis's historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Radiation Dermatitis.
  • The report provides the Radiation Dermatitis epidemiology segmentation by radiotherapy utilization in the 7MM
  • The report provides the Radiation Dermatitis epidemiology segmentation by incident cases of Radiation Dermatitis in the 7MM.
  • The report provides the Radiation Dermatitis epidemiology segmentation by grade-specific cases of Radiation Dermatitis in 7MM.
  • The report provides the Radiation Dermatitis epidemiology segmentation by treated cases of Radiation Dermatitis in 7MM.
Report Highlights
  • 10-year Forecast of Radiation Dermatitis epidemiology
  • 7MM Coverage
  • Radiotherapy Utilization
  • Incident Cases of Radiation Dermatitis
  • Incident Cases according to segmentation: Grade-specific cases of Radiation Dermatitis
  • Incident Cases according to segmentation: Treated cases of Radiation Dermatitis
KOL Views

The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM for the patient population about Radiation Dermatitis?
  • What are the key findings of the Radiation Dermatitis epidemiology across 7MM, and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of Radiation Dermatitis patients across the 7MM during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the study period (2018-2030)?
  • What are the disease risk, burdens, and unmet needs of Radiation Dermatitis?
  • What are the currently available treatments for Radiation Dermatitis?
Reasons to Buy

The Radiation Dermatitis epidemiology report will allow the user to:
  • Develop business strategies by understanding the trends shaping and driving the global Radiation Dermatitis market.
  • Quantify patient populations in the global Radiation Dermatitis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Radiation Dermatitis therapeutics in each of the markets covered.
  • Understand the magnitude of the various cancers by radiotherapy utilization.
  • Understand the magnitude of the Radiation Dermatitis population by its total incident cases.
  • Understand the magnitude of the Radiation Dermatitis population by its grade-specific cases.
  • Understand the magnitude of the Radiation Dermatitis population by its treated cases.
  • The Radiation Dermatitis epidemiology report and model were written and developed by masters and Ph.D. level epidemiologists.
  • The Radiation Dermatitis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030

Radiotherapy is an essential part of cancer treatment and remains a critical and inseparable component of comprehensive cancer treatment and care. In high-income countries, radiotherapy is used in more than half of all cancer cases; these include a cure for localized disease and control disease in incurable cancers. For estimating the total cancer incidence, data regarding the incidence of various cancers were taken from country-specific total incident cases from Global Cancer Observatory (GCO) for 2018 and 2030; growth rate from 2018 to 2030 was utilized to estimate year-on-year country-specific data. Other assessments were also used to get better coverage of cancer incidence, including World Health Organization, Surveillance, Epidemiology, and End Results (SEER), International Agency for Research on Cancer, American Cancer Society, and other institutes and societies. Incidence of major cancer types such as head and neck cancer, breast, lung, prostate, colon, esophagus, and cervix were also pulled-out to show radiation therapy utilization coverage in these cancer types. These cancer types were selected based on a high incidence rate or higher radiation therapy application for treatment.

According to various research articles and Key Opinion Leader (KOL) views, Radiation Dermatitis is a major side effect of radiation exposure that exists on a continuum ranging from erythema to moist desquamation. It was estimated that nearly 95% of patients receiving radiotherapy would ultimately develop some form of radiodermatitis, including erythema, dry desquamation, and moist desquamation during or after the course of treatment. According to an article by Ryan (2012), radiation skin injury occurs in about 95% of patients receiving radiation treatment for cancer. These estimates were used to calculate the incidence of RD in the current forecast.
Note: Product cover images may vary from those shown
2 of 2
1 Key Insights

2 Report Introduction

3 Radiation Dermatitis Market Overview at a Glance
3.1 Market Share (%) Distribution of Radiation Dermatitis in 2018
3.2 Market Share (%) Distribution of Radiation Dermatitis in 2030

4 Executive Summary of Radiation Dermatitis

5 Disease Background and Overview
5.1 Introduction
5.2 Pathophysiology
5.3 Signs and Symptoms
5.4 Risk Factors
5.5 Types of Radiation Dermatitis (RD)
5.6 Clinical manifestations
5.7 Diagnosis
5.8 Grading
5.9 Differential Diagnosis
5.1 Treatment
5.10.1 Treatment of acute radiodermatitis
5.10.2 Treatment of chronic radiodermatitis
5.19.1 ONS Treatment Guidelines

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Incident Population of Radiation Dermatitis
6.3 Epidemiology of Radiation Dermatitis
6.4 The United States
6.4.1 Radiotherapy Utilization in the United States
6.4.2 Incidence of Radiation Dermatitis in the United States
6.4.3 Grade-specific cases of Radiation Dermatitis in the United States
6.4.4 Treated cases of Radiation Dermatitis in the United States
6.5 EU5
6.5.1 Germany
6.5.1.1 Radiotherapy Utilization in Germany
6.5.1.2 Incidence of Radiation Dermatitis in Germany
6.5.1.3 Grade-specific cases of Radiation Dermatitis in Germany
6.5.1.4 Treated cases of Radiation Dermatitis in Germany
6.5.2 France
6.5.2.1 Radiotherapy Utilization in France
6.5.2.2 Incidence of Radiation Dermatitis in France
6.5.2.3 Grade-specific cases of Radiation Dermatitis in France
6.5.2.4 Treated cases of Radiation Dermatitis in France
6.5.3 Italy
6.5.3.1 Radiotherapy Utilization in Italy
6.5.3.2 Incidence of Radiation Dermatitis in Italy
6.5.3.3 Grade-specific cases of Radiation Dermatitis in Italy
6.5.3.4 Treated cases of Radiation Dermatitis in Italy
6.5.4 Spain
6.5.4.1 Radiotherapy Utilization in Spain
6.5.4.2 Incidence of Radiation Dermatitis in Spain
6.5.4.3 Grade-specific cases of Radiation Dermatitis in Spain
6.5.4.4 Treated cases of Radiation Dermatitis in Spain
6.5.5 United Kingdom
6.5.5.1 Radiotherapy Utilization in the United Kingdom
6.5.5.2 Incidence of Radiation Dermatitis in the United Kingdom
6.5.5.3 Grade-specific cases of Radiation Dermatitis in the United Kingdom
6.5.5.4 Treated cases of Radiation Dermatitis in the United Kingdom
6.6 Japan
6.6.1 Radiotherapy Utilization in the United States
6.6.2 Incidence of Radiation Dermatitis in Japan
6.6.3 Grade-specific cases of Radiation Dermatitis in Japan
6.6.4 Treated cases of Radiation Dermatitis in Japan

7 Organizations contributing towards Radiation Dermatitis

8 Patient Journey

9 Case Reports

10 Emerging Therapies
10.1 Key Cross Competition
10.2 Tempol (APC-400): Adamis Pharmaceuticals/Matrix Biomed
10.2.1 Drug Description
10.2.2 Regulatory Milestones
10.2.3 Clinical Development
10.2.4 Clinical Trials Information
10.2.5 Safety and Efficacy
10.2.6 Product Profile
10.3 BMX-001: BioMimetix JV
10.3.1 Drug Description
10.3.2 Regulatory Milestones
10.3.3 Clinical Development
10.3.4 Clinical Trials Information
10.3.5 Safety and Efficacy
10.3.6 Product Profile

11 Radiation Dermatitis: Seven Major Market Analysis
13.1 Key Findings
13.2 Market Size of Radiation Dermatitis in 7MM
13.3 Market Outlook
13.4 United States Market Size
11.4.1 Total Market Size of Radiation Dermatitis in the United States
11.4.2 Market Size of Radiation Dermatitis by Therapies in United States
13.5 EU-5 Market Size
11.5.1 Germany
11.5.1.1 Total Market size of Radiation Dermatitis in Germany
11.5.1.2 Market Size of Radiation Dermatitis by Therapies in Germany
11.5.2 France
11.5.2.1 Total Market size of Radiation Dermatitis in France
11.5.2.2 Market Size of Radiation Dermatitis by Therapies in France
11.5.3 Italy
11.5.3.1 Total Market size of Radiation Dermatitis in Italy
11.5.3.2 Market Size of Radiation Dermatitis by Therapies in Italy
11.5.4 Spain
11.5.4.1 Total Market size of Radiation Dermatitis in Spain
11.5.4.2 Market Size of Radiation Dermatitis by Therapies in Spain
11.5.5 United Kingdom
11.5.5.1 Total Market size of Radiation Dermatitis in the United Kingdom
11.5.5.2 Market Size of Radiation Dermatitis by Therapies in the United Kingdom
13.6 Japan
11.6.1 Total Market size of Radiation Dermatitis in Japan
11.6.2 Market Size of Radiation Dermatitis by Therapies in Japan

12 KOL Views

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 Market Access

18 Appendix
20.1 Bibliography
20.2 Report Methodology

19 Publisher Capabilities

20 Disclaimer

21 About the Publisher

List of Tables
Table 1: Summary of Radiation Dermatitis, Market, Epidemiology, and Key Events (2018-2030)
Table 2: Differences between acute and chronic radiation dermatitis
Table 3: Assessment of chronic radiation dermatitis
Table 4: Summary of Recommendations: ONS Guidelines for Radiodermatitis in Patients With Cancer
Table 5: Total Incident Population of Radiation Dermatitis in 7MM in 000s (2018-2030)
Table 6: Radiotherapy Utilization in the United States (2018-2030)
Table 7: Incidence of Radiation Dermatitis in the United States in 000s (2018-2030)
Table 8: Grade-specific cases of Radiation Dermatitis in the United States (2018-2030)
Table 9: Treated cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Table 10: Radiotherapy Utilization in Germany (2018-2030)
Table 11: Incidence of Radiation Dermatitis in Germany (2018-2030)
Table 12: Grade-specific cases of Radiation Dermatitis in Germany (2018-2030)
Table 13: Treated cases of Radiation Dermatitis in Germany (2018-2030)
Table 14: Radiotherapy Utilization in France (2018-2030)
Table 15: Incidence of Radiation Dermatitis in France (2018-2030)
Table 16: Grade-specific cases of Radiation Dermatitis in France (2018-2030)
Table 17: Treated cases of Radiation Dermatitis in France (2018-2030)
Table 18: Radiotherapy Utilization in Italy (2018-2030)
Table 19: Incidence of Radiation Dermatitis in Italy (2018-2030)
Table 20: Grade-specific cases of Radiation Dermatitis in Italy (2018-2030)
Table 21: Treated cases of Radiation Dermatitis in Italy (2018-2030)
Table 22: Radiotherapy Utilization in Spain (2018-2030)
Table 23: Incidence of Radiation Dermatitis in Spain (2018-2030)
Table 24: Grade-specific cases of Radiation Dermatitis in Spain (2018-2030)
Table 25: Treated cases of Radiation Dermatitis in Spain (2018-2030)
Table 26: Radiotherapy Utilization in the United Kingdom (2018-2030)
Table 27: Incidence of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 28: Grade-specific cases of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 29: Treated cases of Radiation Dermatitis in the United Kingdom (2018-2030)
Table 30: Radiotherapy Utilization in Japan (2018-2030)
Table 31: Incidence of Radiation Dermatitis in Japan (2018-2030)
Table 32: Grade-specific cases of Radiation Dermatitis in Japan (2018-2030)
Table 33: Treated cases of Radiation Dermatitis in Japan (2018-2030)
Table 34: Organization contributing to fight against synovial sarcoma
Table 35: Tempol, Clinical Trial Description, 2021
Table 36: BMX-001, Clinical Trial Description, 2021
Table 37: Seven Major Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 38: United States Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 39: United States Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 40: Germany Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 41: Germany Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 42: France Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 43: France Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 44: Italy Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 45: Italy Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 46: Spain Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 47: Spain Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 48: United Kingdom Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 49: United Kingdom Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)
Table 50: Japan Market Size of Radiation Dermatitis in USD Million (2018-2030)
Table 51: Japan Market Size of Radiation Dermatitis by Therapies in USD Million (2018-2030)

List of Figures
Figure 1: Mechanisms associated with Radiation Dermatitis: inflammation and oxidative stress.
Figure 2: Total Incident Population of Radiation Dermatitis in 7MM in 000s (2018-2030)
Figure 3: Radiotherapy Utilization in the United States in 000s (2018-2030)
Figure 4: Incidence of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 5: Grade-specific cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 6: Treated cases of Radiation Dermatitis in the United States in 000s (2018-2030)
Figure 7: Radiotherapy Utilization in Germany in 000s (2018-2030)
Figure 8: Incidence of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 9: Grade-specific cases of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 10: Treated cases of Radiation Dermatitis in Germany in 000s (2018-2030)
Figure 11: Radiotherapy Utilization in France in 000s (2018-2030)
Figure 12: Incidence of Radiation Dermatitis in France in 000s (2018-2030)
Figure 13: Grade-specific cases of Radiation Dermatitis in France in 000s (2018-2030)
Figure 14: Treated cases of Radiation Dermatitis in France in 000s (2018-2030)
Figure 15: Radiotherapy Utilization in Italy in 000s (2018-2030)
Figure 16: Incidence of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 17: Grade-specific cases of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 18: Treated cases of Radiation Dermatitis in Italy in 000s (2018-2030)
Figure 19: Radiotherapy Utilization in Spain in 000s (2018-2030)
Figure 20: Incidence of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 21: Grade-specific cases of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 22: Treated cases of Radiation Dermatitis in Spain in 000s (2018-2030)
Figure 23: Radiotherapy Utilization in the United Kingdom in 000s (2018-2030)
Figure 24: Incidence of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 25: Grade-specific cases of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 26: Treated cases of Radiation Dermatitis in the United Kingdom in 000s (2018-2030)
Figure 27: Radiotherapy Utilization in Japan in 000s (2018-2030)
Figure 28: Incidence of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 29: Grade-specific cases of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 30: Treated cases of Radiation Dermatitis in Japan in 000s (2018-2030)
Figure 31: Tempol’s protection against radiation-induced toxicity
Figure 32: Seven Major Market Size of Radiation Dermatitis in USD Million (2018-2030)
Figure 33: Market Size of Radiation Dermatitis in the United States, USD Million (2018-2030)
Figure 34: The United States Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 35: Market Size of Radiation Dermatitis in Germany, USD Million (2018-2030)
Figure 36: Germany Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 37: Market Size of Radiation Dermatitis in France, USD Million (2018-2030)
Figure 38: France Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 39: Market Size of Radiation Dermatitis in Italy, USD Million (2018-2030)
Figure 40: Italy Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 41: Market Size of Radiation Dermatitis in Spain, USD Million (2018-2030)
Figure 42: Spain Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 43: Market Size of Radiation Dermatitis in the United Kingdom, USD Million (2018-2030)
Figure 44: The United Kingdom Market Size of Radiation Dermatitis by Therapies in USD Million
Figure 45: Market Size of Radiation Dermatitis in Japan, USD Million (2018-2030)
Figure 46: Japan Market Size of Radiation Dermatitis by Therapies in USD Million
Note: Product cover images may vary from those shown
Adroll
adroll